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Induction of p53odependent and p53.independent
cellular responses by topoisomerase I inhibitors
AC McDonald and R Brown
CRC Department of Medical Oncology, CRC Beatson Laboratories, Garscube Estate, Switchback Road, Glasgow G61 1 BD, UK
Summary We have previously shown that loss of p53 function in A2780 human ovarian adenocarcinoma cells confers increased clonogenic
resistance to several DNA-damaging agents, but not to taxol or camptothecin. We have now extended these studies, comparing wild-type p53-
expressing A2780 cells with isogenic derivatives transfected with a dominant negative mutant (143; val to ala) p53. We show that, as well as
retaining equivalent clonogenic sensitivity to camptothecin, mutant p53 transfectants of A2780 cells do not acquire significantly increased
resistance to the camptothecin analogues topotecan and SN-38, the active metabolite of CPT-11. Compared with vector-alone transfectants
they are, however, relatively (2.2-fold) resistant to GI 147211, a further camptothecin analogue undergoing clinical trial. Treatment of A2780
with camptothecin and each analogue produces an increase, maximal at 24-48 h after drug exposure, of cells in the G/M phase of the cell
cycle and a decrease in both G, and S-phase cells. The G2 arrest is independent of p53 function for camptothecin and the three analogues. All
four compounds can induce apoptosis in A2780, which is reduced in mutant p53 transfectants, as measured using the terminal DNA
transferase-mediated b-d UTP nick end labelling (TUNEL) assay. Thus, although p53-dependent apoptosis is induced by camptothecin,
topotecan and SN-38 in this human ovarian carcinoma cell line, these drugs induce p53-independent death, as measured by clonogenic assay.
Keywords: camptothecin; apoptosis; cell cycle; p53; drug resistance
Despite high rates of response to initial platinum-based
chemotherapy, 5-year survival rates among patients with advanced
ovarian cancer are poor (Young et al, 1993). Early disease recur-
rence in initially responsive patients is associated with resistance
to further platinum therapy (Markman et al, 1991) and there is a
need for novel agents with activity in platinum-resistant and
-refractory disease. The taxoids have activity in disease recurring
after platinum therapy (Kohn et al, 1994). A further group of
drugs also active in recurrent and platinum-resistant disease are
analogues of camptothecin (Takeuchi et al, 1991; Kudelka et al,
1996; Wanders et al, 1996).
Although clinical trials of camptothecin sodium were aban-
doned because of toxicity (Takimoto and Arbuck, 1996), interest
in this class ofdrug was renewed following the identification ofits
mechanism of action as an inhibitor of topoisomerase 1 (Hsiang
and Liu, 1988) and the development of water-soluble analogues
with improved toxicity profiles (Potmesil, 1994). Currently, two
compounds are in advanced development: topotecan has activity
in several tumour types and is licensed for use in platinum-refrac-
tory ovarian cancer (Creemers et al, 1996); irinotecan or CPT-11 is
also active in a number of diseases, most notably large bowel
cancers (Armand et al, 1995). The latter is a pro-drug, converted
by carboxylesterase to the active metabolite SN-38. A third
compound, analogous to topotecan but with enhanced in vitro
activity, is GI 147211 (GG211), currently undergoing phase 2
evaluation (Wanders et al, 1996).
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Mutations of the p53 gene on chromosome 17 are one of the
commonest genetic abnormalities found in human solid tumours,
with a mutation frequency of 30-50% in ovarian cancer (Shelling
et al, 1995). The role of p53 in determining tumour chemosensi-
tivity remains controversial. Recently two groups examining both
p53 immunostaining and p53 mutations have shown clinical corre-
lations between normal p53 protein expression or wild-type (wt)
p53 status and tumour sensitivity to initial cisplatin-based
chemotherapy (Righetti et al, 1996; Buttitta et al, 1997),
supporting previous in vitro observations that loss ofp53 function
may lead to increased drug resistance in ovarian tumour cells
(Brown et al, 1993; Perego et al, 1996). p53 is intimately involved
in the cellular response to DNA damage, being central to two
specific responses, the G,/S cell cycle checkpoint and cell death
via apoptosis (Bates and Vousden, 1996). Alteration in p53 status
is associated with changes in the cellular sensitivity to DNA-
damaging agents; however, in different tumour cell types the
effects of loss of wild-type p53 function on chemosensitivity are
conflicting, with increased sensitivity (Brown et al, 1993;
Hawkins et al, 1996; Wahl et al, 1996), increased resistance
(O'Connor et al, 1993; Fan et al, 1994; Mcllwrath et al, 1994;
Vasey et al, 1996) or unchanged sensitivity (Slichenmeyer et al,
1993) varyingly observed.
The A2780 human ovarian cancer cell line, derived from a
chemo-naive patient, is sensitive to various DNA-damaging
agents (Hamaguchi et al, 1993). It has functional, wt p53 and
undergoes G, arrest following treatment with ionizing radiation
(IR) (Brown et al, 1993). Transfection of a dominant negative
mutant of p53 into A2780 cells causes loss of p53 function as
evidenced by abrogation of an IR-induced G, arrest (Mcllwrath
et al, 1994). The central role of p53 function in determining
sensitivity of these cells to DNA damage is demonstrated by the
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Table 1 Relative sensitivity of A2780/mp53 and A2780/v to camptothecin and analogues
A2780/mp53 A2780/v Relative A2780/mp53 A2780/v Relative
(IC50) (IC50) resistance (IC80) (IC80) resistance
Doxorubicina 70 nM 27 nM 2.6-fold 140 nM 50 nM 2.8
Cisplatina 8 IM 2.5 tM 3.2-fold 16 JM 6.5 gM 2.5
Camptothecin 59 nM 54 nM 1.2-fold 116 nM 104 nm 1.1
Topotecan 200 nM 150 nM 1.3-fold 420 nM 280 nM 1.5
SN-38 40 nM 30 nM 1.4-fold 78 nM 58 nM 1.3
GI 147211 34nM 15 nM 2.3-fold 66 nM 30nM 2.2
Resistance factors are shown for IC50 and IC80 drug concentrations and are derived from regression analysis of survival curves. aThe data for cisplatin and
doxorubicin are from Vasey et al (1996).
GI 147211 Camptothecin
I 1 2 3 4 5 6 | 1 1 2 3 4 5 6 1
I 1 2 3 4 5 6 | 1 2 3 4
SN-38 Topotecan
Figure 1 Induction of p53 protein in A2780 cell line following treatment with camptothecin, GI 147211, SN-38 and topotecan assessed by Western
immunoblotting. All extracts made 24 h following a 1-h drug exposure. Lane 1 in each blot are extracts from untreated controls; lanes 2-6, extracts made
following drug exposure, with concentrations increasing fivefold in sequential lanes. Camptothecin: lane 2, 9.6 nM; lane 3, 0.05 ,UM; lane 4, 0.24 ,UM;
lane 5, 1.2 ,UM; lane 6, 6gm; GI 147211: lane 2, 1.6 nM; lane 3, 8 nM; lane 4, 0.04 gm; lane 5, 0.2gM; lane 6 = 1 gM; SN-38: lane 2, 2.9 nM; lane 3, 14 nM; lane 4,
0.07 gM; lane 5, 0.35 gm; lane 6, 1.8gM; topotecan: lane 2, 12 nM; lane 3, 0.06 gM; lane 4, 0.3 gm; lane 5, 1.5 gm; lane 6, 7.5 gM
increased clonogenic resistance of these mutant p53 transfectants
to several anti-cancer agents, including IR, cisplatin and doxo-
rubicin (Vasey et al 1996). However, this multiagent resistance
profile does not extend to taxol or the topoisomerase 1 inhibitor
camptothecin. Given this spectrum ofdrug resistance and the anti-
tumour activity of topoisomerase 1 inhibitors in early clinical
studies of pretreated and platinum-refractory ovarian cancer
(Kudelka et al, 1996; ten Bokkel Huinik et al 1997), we have eval-
uated the in vitro effects of camptothecin and three water-soluble
analogues within these model systems, specifically examining the
effects ofthese agents on cellular accumulation ofp53 protein, cell
cycle alteration, clonogenic cell sensitivity and apoptosis.
MATERIALS AND METHODS
Cell lines
The following human cell lines were used: A2780, a human
ovarian cancer cell line known to express only wt p53 gene
sequences (Brown et al, 1993); A2780/mp53, an A2780 derivative
transfected with mutant p53 (codon 143, val to ala); A2780/v, a
further A2780 derivative transfected with vector alone (Brown et
al, 1993). A2780/mp53 lacks a radiation-induced GC arrest, which
is retained by A2780/v (Mcllwrath et al, 1994). We have observed
unstable expression ofthis phenotype and therefore regular confir-
mation of abrogation of G, arrest was performed, with cultures
frequently regrown from frozen stocks. All cell lines were main-
tained as monolayers in RPMI-1640 medium with 10% fetal calf
serum (FCS) at 37°C in 95% air/5% carbon dioxide. Continual
positive selection in favour of expression of the linked geneticin
resistance marker was performed for transfectant lines. All cell
lines were free ofMycoplasma contamination.
Drug sensitivity assays
Drug sensitivity was assessed using colony-forming assays; cells
were seeded at 103 into 10-cm2 plates, a range of concentrations
of relevant drug being added 24 h later, for an exposure period of
1 h. Assays were performed in triplicate. Statistical analysis was
determined on six separate assays per line at a defined concentra-
tion ofdrug. After 10 days' incubation, colonies were stained with
Giemsa (BDH) and those with more than 200 cells were counted.
Surviving fractions were calculated as a percentage ofcolonies on
drug-treated relative to untreated plates.
Cell cycle analysis by flow cytometry
Proportions of cells in different phases of the cell cycle were
assessed by incorporation of bromodeoxyuridine (BrdUrd),
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propidium iodide (PI) staining and flow cytometric analysis as
described previously (Mcllwrath et al, 1994). Exponentially
growing cells were plated at 5 x 105 per 10-cm2 plate into medium
and incubated for 3-4 days. Cells were then exposed to growth
medium containing drug for 1 h. At various times after treatment,
medium was replaced by medium containing 10 gM BrdUrd and
cells incubated for 4 h. They were then harvested, fixed, washed
with phosphate-buffered saline (PBS) and partially denatured in 2 N
hydrochloric acid. The cells were incubated with an anti-BrdUrd
mouse MAb (Dako); bound complexes were subsequently detected
with goat anti-mouse fluoroscein isothiocyanate (Sigma), stained
with PI and analysed using a fluorescence-assisted cell sorter
(Becton Dickinson, San Jose, CA, USA). No marked difference in
total cell number was noted between treated and control cultures.
Detection of apoptosis by flow cytometry
Apoptotic cells were detected as described previously (Gorczyca
et al, 1993; Anthoney et al, 1996). Exponentially growing cells
were exposed to either drug-free or drug-containing medium for
1 h and harvested at various times thereafter. Attached and non-
attached cells were collected and fixed firstly in 1% formaldehyde
for 30 min and then 70% ethanol in PBS. Cells were rehydrated in
PBS and aliquots of 106 cells incubated sequentially with cacody-
late buffer (0.2M potassium cacodyalate, 2.5 mM Tris-HCl
(pH 6.6), 2.5 mm cobalt chloride, 0.25 mg ml-' BSA, five units of
terminal DNA transferase/106 cells and 0.5 nmol biotin-dUTP/106
cells) and 4 x SSC/0. 1% Triton X-100 containing 5% Marvel and
5 .tg ml-' fluorosceinated avidin before staining with PI. Cellular
fluoresence was detected using a fluorescence-assisted cell sorter
(Becton Dickinson). !
48
Time (h)
Figure 2 Cell cycle changes over 48 h following a 1-h exposure of A2780,
A2780/mp53 and A2780/v to 0.1 pM camptothecin, an IC0O concentration.
Values (fraction) are expressed as a ratio relative to untreated controls
(which are therefore represented as unity). Values plotted are the mean of at
least four experiments, with error bars representing 1 standard deviation. A
Gl-phase. B S-phase. C G2 M-phase. -*-, A2780; - --- -, A2780/mp53;
- -A- -, A2780/v
Immunoassays
Cell extracts were prepared for p53 and topoisomerase 1
immunoassay by lysing exponentially growing cells as described
previously (Mcllwrath et al, 1994). Protein concentrations were
determined using the Biorad protein assay (Richmond, CA).
Immunoblotting was performed as described previously (Brown et
al, 1993), probed with p53 antibody, (pAB-6 Oncogene Science)
or polyclonal antibody from scleroderma patient serum to topoiso-
merase 1 (Topogen Inc, Columbus, OH, USA). Blots were visual-
ized with enhanced chemiluminescence (Amersham).
RESULTS
Clonogenic sensitivity of A2780/mp53 and A2780/v to
camptothecin and analogues
We have previously shown that mutant p53 cDNA (codon 143 val
to ala) transfected into A2780 cells acts as a dominant negative
mutant and induces loss of an IR-induced GI arrest (Mcllwrath et
al, 1994). These A2780/mp53 transfectants exhibit increased resis-
tance to multiple DNA-damaging agents, such as IR, cisplatin and
doxorubicin, but retain sensitivity to camptothecin (Vasey et al,
1996). We have confirmed the lack of cross-resistance of
A2780/mp53 to camptothecin and examined its sensitivity to the
camptothecin analogues, topotecan, SN-38 and G1147211 (Table
1). At drug concentrations capable ofreducing clonogenic survival
to 50% and 80% of untreated controls (IC.J1/IC80), the mutant p53
transfectants were equivalently sensitive to camptothecin, relative
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Table 2 Cell cycle distribution of A2780/v and A2780/mp53 after drug treatment
Cells in G1 phase (%) Cells in S-phase (%) Cells in G2 phase (%)
A2780/v A2780/mp53 A2780/v A2780/mp53 A2780/v A2780/mp53
Untreated controls 50.2 (1.6) 49 (2.1) 45.4 (3.2) 46.4 (1.8) 4.6 (0.8) 4.4 (1.3)
Ionizing radiation 69.2 (4.4) 53.2 (1.9) 15.8 (1.7) 37.5 (1.8)* 14.5 (3.8) 9.8 (2.2)
Camptothecin 40.6 (3.6) 39.2 (5.8) 24.6 (4.1) 28.8 (2.8) 33.6 (2.7) 31 (4.5)
SN-38 37.6 (4.4) 29 (2.3)* 21.8 (2.5) 31.4 (4.7)* 39 (3.8) 33.8 (2.8)
Topotecan 39.2 (4.2) 30.8 (2.9)* 23.2 (2.3) 32.6 (4.8)* 35 (1.5) 33.5 (2.6)
G1147211 39.6 (2.8) 32.4 (2.9)* 20.8 (1.8) 21.8 (6.7) 39 (3.8) 33.8 (2.8)
The percentage of cells in each phase of the cell cycle, as determined by 4-h pulse BrdUrd labelling and FACS analysis, 24 h after a 1-h exposure to IC80
concentrations of each drug. Figures in brackets represent 1 standard deviation of the mean. *Statistically significant difference between A2780/v and
A2780/mp53 (P < 0.05 using t-test).
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Figure 3 Per cent apoptotic cells in A2780/mp53
drug exposure, as measured by the TUNEL assay.
concentrations used in each case (camptothecin, 0
topotecan, 0.3gM) aside from G1147211 (concentra
A2780/v, but IC50 for A2780/mp53). Error bars repri
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concentration. Similar patterns of induction are observed for
camptothecin, SN-38 and topotecan; however, GI 147211 more
readily induces p53 protein at lower drug concentrations.
Treatment of A2780 with topoisomerase 1 inhibitors at a drug
concentration known to cause 80% reduction in clonogenic
survival (IC80) (0.1 gM camptothecin, 0.3 gM topotecan, 0.07 gM
SN-38 and 0.04 tM GI 147211) for 1 h induces accumulation of
p53 protein within 4-8 hours of treatment, maximal at 24 h
following drug exposure (data not shown). Thus, each of these
topoisomerase 1 inhibitors induces comparable accumulation of
p53 after treatment of A2780 cells.
The p53 protein is a transcriptional transactivator, capable of
influencing expression ofa variety ofgenes (Ko and Prives, 1996).
As we wished to examine cellular responses to topoisomerase 1 SN-38 Topotewan
(0.07gIm) (0.3gtM) inhibitors, it was important to ensure that alteration of p53 status
did not effect levels of expression of topoisomerase 1 in A2780
and A2780/v at 72 h after cells. Cell extracts of A2780 cells transfected with mutant p53
).1 ,UM; SN-38, 0.07 pIM; (codon 143 val to ala: A2780/mp53) were compared with vector-
ition, 0.04,UM, IC80 for alone controls (A2780/v) for expression of topoisomerase 1
esent one standard protein by Western analysis. No difference in the levels oftopoiso- /V
merase 1 was observed between these lines (data not shown),
suggesting that topoisomerase 1 transcription is unaffected by
ce is observed to both changes in p53 status.
topotecan and SN-38 with a more marked 2.2- to 2.3-fold resis-
tance to GI 147211 noted. In order to allow statistical comparison,
surviving fraction was compared between the lines at drug concen-
trations giving approximately 0.2 surviving fraction. Thus, at
concentrations of 0.1 JIM camptothecin, 0.05 gM SN-38 and
0.5 gM topotecan no significant difference in drug sensitivity is
observed between A2780/v and A2780/mp53 (using a Student t-
test). However, A2780/mp53 shows significant cross-resistance to
0.04gM GI 147211 compared with A2780/v (P < 0.01).
Induction of p53 protein accumulation in A2780
We have examined accumulation ofp53 protein after treatment of
A2780 cells with camptothecin and the water-soluble analogues
topotecan, SN38 and GI 147211. Treating A2780 with a range of
drug concentrations, from those causing no detectable effect on
clonogenic survival to doses in excess of that required to produce
100% lethality, leads to p53 protein accumulation 24 h after treat-
ment (Figure 1).
Concentrations ofdrug used in specific lanes are approximately
equitoxic (lane 4 approximating to an IC80 concentration) and the
Cell cycle perturbation induced by the camptothecins
in A2780 and dominant negative mutant p53
transfectants
Treatment ofA2780 with 0.1JIM camptothecin (anID8(0 concentra-
tion) produces a characteristic pattern of cell cycle changes over
48 h following exposure (Figure 2). Changes to the distribution of
cells within the cell cycle are apparent 4 h after drug exposure,
with an increase in cells in the G2/M phase. This increase is
maximal at 24 h, with a five- to tenfold accumulation of cells
within GI/M phase. Treatment with camptothecin also leads to a
reduction in S-phase cells, again maximal at 24 h.
A2780 cells transfected with a dominant negative mutant ofp53
lose an IR-induced G6 arrest, whereas the G2 arrest is unaffected
(Mcllwrath et al, 1994). As shown in Table 2, the per cent of S-
phase cells in vector-alone transfectants of A2780 (A2780/v) is
reduced from 45.4% to 15.8% after irradiation with 2-Gy y-rays,
with a concomitant increase in the percentage ofG, cells. Mutant
p53 transfectants (A2780/mp53) show markedly less reduction in
per cent S-phase cells and little increase in the per cent GC cells.
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An ID8( concentration of camptothecin induces no statistically
significant difference in the per cent S-phase or G2/M phase cells
between vector controls and mutant p53 transfectants (Table 2).
Using ID80 concentrations of topotecan, SN-38 and GI 147211
similar patterns of increase in G,/M cells were observed in A2780/v
and A2780/mp53, with an approximately eight-fold accumulation
ofcells in GJM (Table 2). Although there was a reduction in the per
cent S-phase cells 24 h after drug treatment, there was a greater
reduction in the vector-alone controls compared with the mutant
p53 transfectants, with this difference reaching statistical signifi-
cance for topotecan and SN38 (Table 2). In addition, although both
transfected lines showed a reduction in GI phase cells, this was
more pronounced in the mutant p53 transfectants. Reduction in S-
phase cells can be indicative of a G, arrest; however, the reduction
in S-phase cells may also partly be due to the pronounced G, arrest
preventing cells from entering G, and eventually S-phase. Thus, it
appears that these tumour cells undergo p53-dependent and -inde-
pendent cell cycle arrests induced by SN-38 and topotecan, the
G,/M arrest occurring independently of p53 status and the G, to S
transition exhibiting partial p53 dependence.
Apoptosis in A2780 induced by the camptothecins
We have used flow cytometry to detect and quantify DNA strand
breakage in cells, using fluorescent (FITC) end labelling by
terminal transferase (TUNEL assay) as a semiquantitative measure
of apoptosis in A2780 and its derivatives. This technique has
previously been validated for A2780 by examination of cellular
morphology, demonstrating that FITC-positive cells have an apo-
ptotic morphology (data not shown), and by non-random cleavage
of DNA (Anthoney et al, 1996). Following treatment of A2780
cells for I h with concentrations of camptothecin and its three
analogues double that required to induce 80% cell kill, cells were
harvested over the following 4 days and analysed using the
TUNEL assay. The fraction ofFITC-positive cells was maximal at
72-96 h after drug exposure and this increase in FITC-positive
cells was temporally associated with the appearance of a sub-G,
population of cells on DNA content histograms (data not shown).
Whereas the absolute magnitude of FITC-positive cells varied
with each experiment, in general maximal levels of apoptosis
observed were of the order of 5-25% ofcounted cells.
Apoptosis induced by camptothecin, SN-38, topotecan and GI
147211 was measured in A2780/mp53 and A2780/v cells using the
TUNEL assay. Maximum apoptosis was again observed at 72-96 h
after drug exposure. Cells were exposed to IC o concentrations
(relative to A2780/v cells) ofeach drug. For each compound signif-
icantly more apoptosis (range 5.3- to 6.6-fold) was observed in
A2780/v than in A2780/mp53, suggesting that apoptosis induced
by these agents in these cell lines is dependent on the presence ofwt
p53 (Figure 3). This p53-dependent apoptotic profile was observed
with GI 147211 even when used at equitoxic concentrations for
A2780/mp53 (60 nM) and A2780/v (30 nM), based on clonogenic
assay (fold difference in apoptosis = 3.2, data not shown). Cisplatin
induced significantly more apoptosis in both cell lines, although
again with a p53-dependent profile (A2780/mp53 = 12%;
A2780/v = 50%, ratio = 4.2-fold, data not shown).
DISCUSSION
We have previously shown that transfection of A2780 cells with a
dominant negative mutant p53 gene (codon 143, val to ala)
produces measurable loss of p53-mediated cell cycle regulatory
function (Mcllwrath et al, 1994) and confers resistance to multiple
DNA-damaging agents, measured by colony-forming assays
(Vasey et al, 1996). However, this drug resistance profile does not
extend to camptothecin nor, as we now show, to two water-soluble
camptothecin analogues, topotecan and SN-38. Thus, in contrast to
agents such as IR, cisplatin and doxorubicin, reproductive cell
death induced by these agents (as measured by the clonogenic assay
in these A2780 derived cell lines) is not dependent on the presence
offunctioning p53. The mutant p53 transfectants exhibit resistance
to a third camptothecin analogue, GI 147211, and, although this
resistance is low-fold, it is of a magnitude similar to that which we
have previously observed for other agents (Vasey et al, 1996).
DNA damage is capable of inducing cellular accumulation of
p53 protein in many model systems (Fritsche et al, 1993). We have
previously described p53 induction in A2780 (Mcllwrath et al,
1994) by IR and cisplatin. It is thought that the stimulus for such
post-translational protein accumulation is DNA double-strand
breakage, and, indeed, the initial work proposing this hypothesis
was performed using camptothecin (Nelson and Kastan, 1994). We
show that camptothecin and the three analogues studied induce
accumulation of p53 in A2780. This accumulation varies with
drug concentration, but is clearly apparent following treatment
with concentrations (IC80) relevant to cell death, as measured
by colony-forming assays. Furthermore, A2780 cells undergo
measurable p53-dependent apoptosis (as assessed by the TUNEL
assay) 72-96 h following exposure to drug concentrations relevant
to inhibition of colony formation. These observations suggest that
A2780 cells can initiate p53-mediated responses to the DNA
damage induced by these agents, but this is not reflected in a p53
dependence on clonogenic drug sensitivity.
Analysis ofcell cycle changes following treatment ofA2780 cells
with camptothecin and its analogues reveals a complex series of
events, with two major patterns ofcell cycle perturbation observed.
The most striking feature is a 5- to 10-fold accumulation ofcycling
cells in the G/M phase 24 h following topoisomerase 1 inhibitor
treatment. This is associated with a reduction ofcells within both the
G, and S-phase compartments, which can be in part attributed to the
block in GJM impeding cell cycle progression. The cell cycle
effects of carnptothecin have been widely studied (del Bino et al,
1990; Goldwasser et al, 1996), with most workers describing a
similar GJM or S-phase accumulation. Treatment of A2780/mp53
and A2780/v with camptothecin and the three analogues induces a
G,/M arrest in both cell lines ofequal magnitude, and which is there-
fore a p53-independent event. The S-phase depletion observed in
A2780 is also seen in the dominant negative mutant p53 transfected
line, but the magnitude of the reduction in S-phase cells for
topotecan- and SN-38-treated cells is at least partially p53 depen-
dent. This suggests that, despite the lack ofsignificantGI accumula-
tion, the depletion of the S-phase compartment observed is in part
due to impaired transit across the G,/S cell cycle checkpoint in
A2780/v. Importantly, however, both cell cycle changes and cell
death, as measured by colony formation, induced by camptothecin
are independent of p53 status and thus distinct from changes
induced by at least two ofthe three camptothecin analogues studied.
Apoptosis (as measured by the TUNEL assay) induced by
camptothecin, SN-38 and topotecan is clearly reduced ifp53 func-
tion is inhibited, whereas cell death induced by these drugs, as
measured by clonogenic assay, is mainly unaffected by p53 status.
This is contrary to observations made with IR and cisplatin in
these lines, where inhibition of p53 function leads to reduced
induction of apoptosis and increased clonogenic resistance (Vasey
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et al, 1996). Even treatment of A2780/mp53 with an IC8(0 concen-
tration ofGI 147211 (0.06 tM) still induced less apoptosis than an
equitoxic treatment of A2780/v (0.03 JtM, data not shown). The
inhibitors of topoisomerase 1 do not appear to be proficient
inducers of TUNEL-detectable apoptosis, when compared with
cisplatin. However, there is a disparity between the p53 indepen-
dence of cell survival observed on clonogenic assay and the p53
dependence of cell killing by apoptosis. This suggests that p53-
dependent apoptosis, as measured, is not the main mechanism
leading to cell death produced in vitro by these agents at the
concentrations studied. Which of these two measures of cellular
response reflects most closely the in vivo situation is unclear;
some workers, using cell lines of varied p21 status, have found
that clonogenic assays fail to predict the observed response to
treatment using in vivo models (Waldman et al, 1997).
It is tempting to speculate that there is a connection between the
patterns of cell cycle perturbation produced by these compounds
and the clonogenic assay data. Is the ability of these agents to
induce p53-independent cell death related to their ability to induce
a p53-independent G,/M cell cycle arrest? Arrest of cells in G,/M
is a common feature induced by many cytotoxics (Barlogie and
Drewinko, 1978) and by no means exclusive to inhibitors of topo-
isomerase 1. The stimulus for this arrest is thought to be double-
stranded DNA breakage and, although there is some evidence
suggesting a role for p53 in the control of the G2/M checkpoint,
this remains unclear (Kastan et al, 1991; Agarwal et al, 1995;
Stewart et al, 1995). However, the p53 dependence of clonogenic
cell death produced by GI 147211 would argue against any role for
GJ/M arrest in lethality, given the ability of this compound to
induce identical patterns of cell cycle perturbation at concentra-
tions with which there is a clear differential in clonogenic survival.
Finally, although camptothecin has been shown to down-regulate
p34/cyclin B (Tsao et al, 1992), the function of the G}/M check-
point is unknown and there is no clear evidence linking specific
patterns of topoisomerase 1 inhibitor-induced cell cycle changes
with the induction of cell death (del Bino et al, 1990; Cotter et al,
1992; Pantazis et al, 1993; Goldwasser et al, 1996).
Given the developing correlation between p53 status and
response to platinum-based chemotherapy (Righetti et al, 1996;
Buttitta et al, 1997) and our observations of the p53 independent
efficacy ofcamptothecin analogues in a platinum-resistant, mutant
p53 ovarian cell line model, it is reasonable to hypothesize that
these observations at least partly explain the observed clinical
activity of these drugs in tumours resistant to conventional
therapy. Our findings clearly support the evolving role for the
camptothecin analogues in this group of tumours and suggest that
this class ofdrug should be further evaluated in other tumour types
likely to harbour p53 mutations either at presentation or relapse.
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